{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:40:50Z","timestamp":1782510050492,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lenvatinib, a multi-kinase inhibitor widely used in the treatment of radioiodine-refractory differentiated thyroid carcinoma (RR-DTC), has shown remarkable efficacy and improvement in progression-free survival (PFS), although its use is associated with a variety of side effects. Among them, adrenal insufficiency (AI) remains under-recognized and potentially underestimated, and it may be involved in fatigue, one of the most frequent adverse events (AEs) Lenvatinib-related. In this prospective study, we report the incidence, development, and time course of primary AI (PAI) during Lenvatinib treatment in patients with RR-DTC followed at a single tertiary care center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was conducted on 39 consecutive patients with RR-DTC. Eight patients were excluded because they had a follow-up of less than 6 months or were receiving glucocorticoids for RR-DTC-related indications. We studied 31 patients selected for Lenvatinib therapy from June 2017 to December 2024. The median follow-up duration was 42.58 \u00b1 29.53 months (range, 6\u201397 months). Performance status was evaluated for each patient using the Eastern Cooperative Oncology Group (ECOG) scale. Adrenal function was assessed by measuring serum cortisol and adrenocorticotropic hormone (ACTH) levels, and through the 250 \u03bcg ACTH stimulation test. Additionally, fatigue intensity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale. Peak cortisol levels below 500 nmol\/L (18.1 \u00b5g\/dL) at 30 or 60 minutes after ACTH injection were indicative of adrenal insufficiency (AI) (PAI-18.1). A cutoff of 386.2 nmol\/L (14 \u00b5g\/dL) has also been used (PAI-14). In patients with primary adrenal insufficiency (PAI), steroid replacement therapy with cortisone acetate (CA) was initiated at doses ranging from 25 to 37.5 mg\/day. Throughout follow-up, the ACTH stimulation test was repeated every 3 to 9 months, with a 72-hour discontinuation of CA prior to testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During Lenvatinib treatment, 24 of 31 patients (77.4%) developed primary AI (PAI)-18.1, and 14 of 31 patients (45.2%) developed PAI-14. Patients with a cortisol peak below 646.6 nmol\/L at the initial ACTH stimulation test, prior to starting Lenvatinib, demonstrated a higher risk of developing both PAI-18.1 and PAI-14 during treatment. Patients who developed PAI during Lenvatinib treatment had significantly lower cortisol peak levels on the initial ACTH stimulation test performed before treatment initiation compared to those who did not develop PAI. Fatigue was observed in 28 of 31 patients (90%) during Lenvatinib treatment. Among patients who developed PAI, a significant improvement in fatigue was observed following initiation of CA therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest a higher occurrence of PAI, which may contribute to fatigue associated with Lenvatinib treatment. Routine adrenal function testing and early recognition of PAI are essential for timely diagnosis and effective glucocorticoid replacement therapy, enabling patients to continue Lenvatinib treatment with improved tolerability and adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1691740","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:20Z","timestamp":1767591020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency"],"prefix":"10.3389","volume":"16","author":[{"given":"Salvatore","family":"Monti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fazzalari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Renzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bongermino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Lioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Deiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedra","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac065","article-title":"Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit","volume":"27","author":"Wirth","year":"2022","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in Radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae181","article-title":"Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in real life","volume":"109","author":"Marotta","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of Lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01836","article-title":"Primary adrenal insufficiency during lenvatinib or vandetanib and improvement of fatigue after cortisone acetate therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1089\/thy.2021.0040","article-title":"Cortisol deficiency in lenvatinib treatment of thyroid cancer: an underestimated common adverse event","volume":"32","author":"Monti","year":"2022","journal-title":"Thyroid."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02025-3","article-title":"Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test","volume":"46","author":"Valerio","year":"2023","journal-title":"J Endocrinol Invest."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0246","article-title":"Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex","volume":"13","author":"Colombo","year":"2024","journal-title":"Eur Thyroid J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf123","article-title":"Mild primary adrenal insufficiency during treatment with lenvatinib and pembrolizumab: A report of 3 patients","volume":"3","author":"Yamabayashi","year":"2025","journal-title":"JCEM Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"bvab022","DOI":"10.1210\/jendso\/bvab022","article-title":"New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays","volume":"5","author":"Javorsky","year":"2021","journal-title":"J Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301331110","article-title":"Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200011)185:2<226::AID-JCP7>3.0.CO;2-E","article-title":"ACTHregulated expression of vascular endothelial growth factor in the adult bovine adrenal cortex: a possible role in the maintenance of the microvasculature","volume":"185","author":"Gaillard","year":"2000","journal-title":"J Cell Physiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/cancers12041010","article-title":"Weekends-off lenvatinib for unresect able hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events","volume":"12","author":"Iwamoto","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032557","article-title":"Variations in cortisol response in patients with known and suspected adrenal insufficiency","volume":"101","author":"Mahzari","year":"2022","journal-title":"Med (Baltimore)."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02477-0","article-title":"Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival","volume":"72","author":"De Leo","year":"2021","journal-title":"Endocrine."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02290-9","article-title":"Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina","volume":"69","author":"Jerkovich","year":"2020","journal-title":"Endocrine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000508186","article-title":"Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients\u2019 Perspective beyond the Medical Evaluation","volume":"10","author":"Nervo","year":"2021","journal-title":"Eur Thyroid J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12020-017-1499-7","article-title":"Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice","volume":"59","author":"Molina-Vega","year":"2018","journal-title":"Endocrine."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1691740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:21Z","timestamp":1767591021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1691740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":24,"alternative-id":["10.3389\/fendo.2025.1691740"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1691740","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1691740"}}